Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (31)

I-001Freya Bachmann

Prospective dose optimization for individual patients by successive application of empirical Bayesian estimation and OptiDose including uncertainty quantification: Application to pediatric Graves’ Disease

Wed, Jun 3, 2026 10:30AM–12:00PM

I-002Wendy Chu

Female contraceptive cover duration for miltefosine-containing regimens for the treatment of leishmaniasis

Wed, Jun 3, 2026 10:30AM–12:00PM

I-003Astrid Heida

Structured fit-for-purpose evaluation of model-informed precision dosing of mycophenolic acid and tacrolimus in pediatric patients with renal disease

Wed, Jun 3, 2026 10:30AM–12:00PM

I-004Toni Michael

POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELLING OF FOLLICLE-STIMULATING HORMONE AND INHIBIN-B TO PREDICT OVARIAN RESPONSE TO FOLLITROPIN ALFA IN IN VITRO FERTILISATION PATIENTS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-005Paulina Okuńska

Individualized Vancomycin Dosing Using Bayesian Modeling in Pediatric Patients with Lymphomas and Leukemias

Wed, Jun 3, 2026 10:30AM–12:00PM

I-006Keith T. Schmidt

Pharmacometric evaluation of extended interval dosing of IV-administered nivolumab using an established popPK model and sparse trough sampling: REFINE Nivolumab Cohort Interim Pharmacokinetic Analysis

Wed, Jun 3, 2026 10:30AM–12:00PM

I-007Alma Tan

OPTIMIZING DOSING REGIMENS OF TRASTUZUMAB EMTANSINE AND TRASTUZUMAB DERUXTECAN: A MODEL-INFORMED COST-SAVING APPROACH

Wed, Jun 3, 2026 10:30AM–12:00PM

I-008Lu Turković

Adherence to Ribociclib Treatment: Insights from Population Pharmacokinetic Simulations and Plasma Concentration Measurements

Wed, Jun 3, 2026 10:30AM–12:00PM

II-001Katharina Braun

Prospective randomised controlled trial on model-informed precision dosing (MIPD) for ustekinumab and vedolizumab in inflammatory bowel diseases (MOVE-IT): A Bayesian framework incorporating parameter uncertainty

Wed, Jun 3, 2026 3:20PM–4:50PM

II-002Cleo Demeester

BUILDING AN OPEN-SOURCE SUB-SAHARAN AFRICAN PBPK POPULATION: INTEGRATING ANATOMICAL, PHYSIOLOGICAL, AND ENZYMATIC VARIABILITY

Wed, Jun 3, 2026 3:20PM–4:50PM

II-003Omnia S. Heikal

Modeling of Vancomycin-Induced Changes in Serum Creatinine to Improve Prediction of Acute Kidney Injury

Wed, Jun 3, 2026 3:20PM–4:50PM

II-004Nandawula Habra

Exposure Comparison of Standard Versus Alternate Hydroxyurea Dosing in Ugandan Children with Sickle Cell Disease: A Non-Compartmental Pharmacokinetic Analysis

Wed, Jun 3, 2026 15:20PM–16:50PM

II-005Venkatesh Pilla Reddy

Translational PK/PD modelling of sofetabart mipitecan, an antibody-drug conjugate linked to exatecan via a novel cleavable polysarcosine linker

Wed, Jun 3, 2026 3:20PM–4:50PM

II-006Carlos Serra Traynor

KPD-ML PREDICTION OF DOCETAXEL‑INDUCED NEUTROPENIA IN LARGE RWE DATASETS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-007Zhiyuan Tan

Characterization of real-world pembrolizumab population pharmacokinetics in cancer patients: towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval

Wed, Jun 3, 2026 3:20PM–4:50PM

II-008Zhiheng Yu

Does Nonlinear Absorption of Oral Misoprostol Challenge Guideline-Based Dosing in Late Pregnancy Cervical Ripening? A Population Pharmacokinetic Model to Resolve.

Wed, Jun 3, 2026 3:20PM–4:50PM

III-001Massimiliano Germani

Model-informed pediatric drug development for clevidipine

Thu, Jun 4, 2026 9:50AM–11:20AM

III-002Núria Folguera Blasco

TEZEPELUMAB POPULATION PHARMACOKINETICS SUPPORTS PAEDIATRIC EXTRAPOLATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)

Thu, Jun 4, 2026 9:50AM–11:20AM

III-003Yannick Hoffert

A population pharmacokinetics and exposure–response framework for tacrolimus dose optimization in intestinal transplantation

Thu, Jun 4, 2026 9:50AM–11:20AM

III-004Anh Thi Van Nguyen

Impact of PK/PD indices on target attainment of vancomycin therapy in critically ill children: back to the drawing board

Thu, Jun 4, 2026 9:50AM–11:20AM

III-005Baralee Punyawudho

Dolutegravir dose optimization based on population pharmacokinetics and pharmacogenetics in Thai people living with HIV

Thu, Jun 4, 2026 9:50AM–11:20AM

III-006Nelleke Snelder

QUANTIFICATION OF INDIVIDUAL Β-CELL FUNCTION AND INSULIN SENSITIVITY: TOWARDS PERSONALISED LIFESTYLE AND MEDICINE TREATMENT

Thu, Jun 4, 2026 9:50AM–11:20AM

III-007Woan Torng Tang

Population Pharmacokinetics/Pharmacodynamics (PK/PD) and Time-to-Event (TTE) Analysis of Major Bleeding for Rivaroxaban-Treated Patients with Atrial Fibrillation: Assessing the Influence of Heart Failure through Left- and Right-Ventricular Performance Markers

Thu, Jun 4, 2026 9:50AM–11:20AM

III-008Wei Zhang

POPULATION PHARMACOKINETICS AND EXPOSURE–RESPONSE MODELING SUPPORTS OPTIMIZED USTEKINUMAB INDUCTION DOSING IN CHRONIC POUCHITIS

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-001Xiaoying Chen

DOSE SELECTION BY A MODEL-INFORMED DRUG DEVELOPMENT (MIDD) APPROACH FOR NAPORAFENIB AND TRAMETINIB COMBINATION IN PATIENTS WITH MELANOMA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-002Jesika Habip Gatenyo

A PK/PD WORKFLOW TO SUPPORT THE SELECTION OF EMPIRICAL ANTIBIOTIC COMBINATIONS: APPLICATION TO NEONATAL SEPSIS IN LOW- AND MIDDLE-INCOME COUNTRIES

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-003Han Liu

Sex differences in sunitinib tolerability and patient-reported outcomes in metastatic renal cell carcinoma: the role of exposure and implications for precision dosing

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-004Van Dong Nguyen

Assessing Vancomycin PK Model Performance Across Trough- and AUC-Based Targets in Diverse Patient Populations

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-005Razan Sakran

Development and Evaluation of an Optimized Busulfan Dosing Strategy in Hematopoietic Stem Cell Transplantation

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-006Johannes Starp

DOES THEORETICAL TARGET ATTAINMENT REFLECT REAL-WORLD TARGET ACHIEVEMENT? AN EVALUATION IN INTENSIVE CARE UNIT PATIENTS RECEIVING PIPERACILLIN AS CONTINUOUS INFUSION

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-007THI THANH TRAN

Physiologically Based Pharmacokinetic Modeling of Rilpivirine to Support Trimester-Specific Dose Optimization in Pregnant Women Living With HIV

Thu, Jun 4, 2026 1:40PM–3:10PM